当前位置: X-MOL 学术J. Clin. Oncol. › 论文详情
Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)
The Case for Maintenance Pemetrexed Plus Bevacizumab.
Journal of Clinical Oncology ( IF 45.3 ) Pub Date : 2020-01-02 , DOI: 10.1200/jco.19.02348
Nasser Hanna 1 , Shadia Jalal 1
Affiliation  

Ramalingam et al1 reported the results of a phase III trial, ECOG-ACRIN 5508, which compared maintenance bevacizumab versus pemetrexed versus the combination in patients with advanced nonsquamous non–small-cell lung cancer (NSCLC) who had stable or responding disease after induction carboplatin plus paclitaxel plus bevacizumab. The authors stated that “we can definitively conclude that the combination of bevacizumab and pemetrexed cannot be recommended as maintenance therapy.”

中文翻译:

培美曲塞加贝伐单抗维持治疗的情况。

Ramalingam等[ 1]报告了一项ECOG-ACRIN 5508 III期临床试验的结果,该试验比较了贝伐单抗与培美曲塞与联合治疗对晚期非鳞状非小细胞肺癌(NSCLC)患者在诱导后病情稳定或有反应的患者中的维持作用卡铂加紫杉醇加贝伐单抗。作者指出:“我们可以明确地得出结论,不建议将贝伐单抗和培美曲塞联用作为维持治疗。”
更新日期:2020-02-27
down
wechat
bug